METHODS AND COMPOSITIONS COMPRISING ANTI-CD3 ANTIBODIES AND DYRK1A INHIBITORS FOR TREATING DIABETES

ABSTRACT

Provided herein are methods and compositions for treating type 1 diabetes. Also provided herein are methods and compositions for preventing or delaying the onset of type 1 diabetes. In some embodiments, such method can include administering to a subject in need thereof a 12-day to 14-day course of teplizumab at a total dose of about 9000 μg/m2 to about 14000 μg/m2 and administering an effective amount of a DYRK1A inhibitor.

[Figure 1]